<abstract xmlns="http://www.w3.org/1999/xhtml">

<sec><h3>AIM</h3>
<p>The aim of the study was to evaluate cardiovascular risk in patients with diabetes mellitus type 2 according to gender.</p>
</sec>
<sec><h3>METHODS</h3>
<p>The monitoring was designed as a retrospective analysis of data obtained from the documentation of the diabetic outpatients treated with the dipeptidyl peptidase-4 inhibitors (DPP4is) or sodium–glucose co-transporter-2 (SGLT2). Cardiovascular risk was assessed according to UKPDS risk engine.</p>
</sec>
<sec><h3>RESULTS</h3>
<p>The levels of HbA1c decreased throughout the whole study. Sixty per cent of patients achieved an HbA1c level &lt;8% after 18 months. Both men and women had similar glycaemic compensation. Men had a significantly higher risk of fatal coronary heart disease (CHD) (<italic>p</italic> &lt; 0.001), stroke (<italic>p</italic> &lt; 0.01) and fatal stroke (<italic>p</italic> &lt; 0.01) compared to women. We found the risk of fatal CHD to be 38-fold higher in men compared to women (<italic>p</italic> &lt; 0.01).</p>
</sec>
<sec><h3>CONCLUSION</h3>
<p>Potential cardiovascular effects of antidiabetic treatment should be clearly defined with possible different effects according to gender. We found a much higher risk in men than women, even when their glycaemic compensation was comparable.</p>
</sec>
</abstract>

AIM
The aim of the study was to evaluate cardiovascular risk in patients with diabetes mellitus type 2 according to gender.

METHODS
The monitoring was designed as a retrospective analysis of data obtained from the documentation of the diabetic outpatients treated with the dipeptidyl peptidase-4 inhibitors (DPP4is) or sodium–glucose co-transporter-2 (SGLT2). Cardiovascular risk was assessed according to UKPDS risk engine.

RESULTS
The levels of HbA1c decreased throughout the whole study. Sixty per cent of patients achieved an HbA1c level <8% after 18 months. Both men and women had similar glycaemic compensation. Men had a significantly higher risk of fatal coronary heart disease (CHD) (p < 0.001), stroke (p < 0.01) and fatal stroke (p < 0.01) compared to women. We found the risk of fatal CHD to be 38-fold higher in men compared to women (p < 0.01).

CONCLUSION
Potential cardiovascular effects of antidiabetic treatment should be clearly defined with possible different effects according to gender. We found a much higher risk in men than women, even when their glycaemic compensation was comparable.

The Evaluation of Cardiovascular Risk in Diabetic Patients

European Pharmaceutical Journal

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

{"article-title":"The Evaluation of Cardiovascular Risk in Diabetic Patients"}

AIM
The aim of the study was to evaluate cardiovascular risk in patients with diabetes mellitus type 2 according to gender.

METHODS
The monitoring was...

The Evaluation of Cardiovascular Risk in Diabetic Patients

Article Category: Original Paper

Publié en ligne: 04 avr. 2022

Pages: 1 - 8

Reçu: 06 août 2021

Accepté: 05 nov. 2021

DOI: https://doi.org/10.2478/afpuc-2022-0001

Mots clés
diabetes, UKPDS, coronary heart disease, stroke, gender

© 2022 S. Kosirova et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

The Evaluation of Cardiovascular Risk in Diabetic Patients

Article Category: Original Paper

Publié en ligne: 04 avr. 2022

Pages: 1 - 8

Reçu: 06 août 2021

Accepté: 05 nov. 2021

DOI: https://doi.org/10.2478/afpuc-2022-0001

Mots clésdiabetes, UKPDS, coronary heart disease, stroke, gender

© 2022 S. Kosirova et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Mots clés
diabetes, UKPDS, coronary heart disease, stroke, gender